Malignant lymphoma after diphenylhydantoin (dilantin) therapy.
A history of prolonged diphenylhydantoin (Dilantin) therapy was reported by 8 of 516 patients (1.6%) with Hodgkin's disease or non-Hodgkin's lymphoma, as compared with 3 of 516 patients (0.6%) with other cancers, and 2 of 516 (0.4%) tumor-free individuals. The findings, together with other published data, suggest a small excess risk of malignant lymphomas in patients receiving long-term treatment with this drug. The immunosuppressive effects of chronic diphenylhydantoin therapy may be involved in the pathogenesis of these neoplasms.
D000328:Adult; D005260:Female; D006689:Hodgkin Disease / Q000139:chemically induced; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use
D010672:Phenytoin